Cerus Corporation - צמיחת מכירות משנה לשנה (TTM) CERS

The global reach of biomedical system sales markets reduces risks for Cerus Corporation (CERS), while stable demand for INTERCEPT ensures predictable revenue. The TTM year-over-year sales volume dynamics visualize revenue volatility, where the 13.60 level reflects the current value of the metric. The efficiency of the business model is supported by outsourcing equipment assembly and optimized logistics for consumables.
Cerus Corporation - פילוחים אנליטיים ומדדי מפתח (CERS)

The expansion of the INTERCEPT system into global blood transfusion centers directly determines the scaling pace of Cerus Corporation (CERS). Analyzing the sales dynamics over the last 12 months on a year-over-year basis, an investor sees a smoothed percentage revenue growth that strips seasonality from the trend and confirms real demand for pathogen inactivation technologies, signaling a balance between the asset's price growth and its fundamental value.